Key Takeaways
- • The UK's Advanced Research and Invention Agency (Aria) has allocated £50 million—approximately 12.5% of its £400 million two-year R&D budget—to 14 US tech companies and venture capital groups, raising questions about domestic benefit requirements.
- • Rain Neuromorphics, a US neuromorphic computing firm backed by OpenAI chief executive Sam Altman, received Aria funding despite being reported near collapse in 2025 and having lost at least two founders; the company remains contracted to deliver projects for Aria.
- • Aria, created by former senior advisor Dominic Cummings to fund "moonshot" research and "restore Britain's place as a scientific superpower," is facing increased parliamentary scrutiny over whether its spending aligns with statutory obligations to drive UK economic growth and innovation.
- • Critics, including University College London economics professor Cecilia Rikap, argue the agency is effectively using taxpayer money to expand the influence of the US tech ecosystem rather than advance British scientific and economic interests.
- • Chi Onwurah, chair of the Commons Science and Technology Committee, has signaled the need for stronger oversight of Aria's allocation decisions following the agency chair's 2025 appearance before Parliament.
Summary
Britain's Advanced Research and Invention Agency has committed £50 million of public funding to US-based technology companies and venture capital firms, according to a joint investigation by the Guardian and Democracy for Sale. The allocation represents over one-eighth of Aria's £400 million research and development budget deployed over the past two years, directing substantial taxpayer resources to overseas entities in some cases with unclear returns to the UK economy or the agency itself.
Aria, established under the vision of Dominic Cummings to fund experimental and high-risk "moonshot" innovation projects, was designed as a mechanism to position Britain as a scientific superpower. However, the concentration of funding flowing to American tech ventures has triggered criticism from both academic economists and parliamentary oversight bodies. Among the 14 US entities receiving grants is Rain Neuromorphics, a neuromorphic computing company backed by OpenAI chief executive Sam Altman. The company faced reported financial distress in 2025, shortly after securing Aria funding, and has experienced leadership turnover with at least two founders departing. Despite these challenges, Rain Neuromorphic remains under contract to deliver projects for Aria.
The agency's spending priorities have drawn scrutiny from the Commons Science and Technology Committee. Chi Onwurah, the committee chair, emphasized that the Aria Act explicitly requires the organization to benefit the UK by driving economic growth, supporting scientific innovation, and improving quality of life. Onwurah noted that the agency chair acknowledged the need for stronger scrutiny during a 2025 parliamentary appearance.
University College London economics professor Cecilia Rikap characterized the funding strategy as expanding US tech sector dominance under the guise of moonshot research, arguing the approach serves American commercial interests rather than British scientific advancement. The findings highlight an emerging tension between Aria's mandate to foster UK innovation leadership and its capital allocation patterns favoring overseas technology ventures.
Aria, established under the vision of Dominic Cummings to fund experimental and high-risk "moonshot" innovation projects, was designed as a mechanism to position Britain as a scientific superpower. However, the concentration of funding flowing to American tech ventures has triggered criticism from both academic economists and parliamentary oversight bodies. Among the 14 US entities receiving grants is Rain Neuromorphics, a neuromorphic computing company backed by OpenAI chief executive Sam Altman. The company faced reported financial distress in 2025, shortly after securing Aria funding, and has experienced leadership turnover with at least two founders departing. Despite these challenges, Rain Neuromorphic remains under contract to deliver projects for Aria.
The agency's spending priorities have drawn scrutiny from the Commons Science and Technology Committee. Chi Onwurah, the committee chair, emphasized that the Aria Act explicitly requires the organization to benefit the UK by driving economic growth, supporting scientific innovation, and improving quality of life. Onwurah noted that the agency chair acknowledged the need for stronger scrutiny during a 2025 parliamentary appearance.
University College London economics professor Cecilia Rikap characterized the funding strategy as expanding US tech sector dominance under the guise of moonshot research, arguing the approach serves American commercial interests rather than British scientific advancement. The findings highlight an emerging tension between Aria's mandate to foster UK innovation leadership and its capital allocation patterns favoring overseas technology ventures.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.